-
Je něco špatně v tomto záznamu ?
Myo-inositol rescued insulin resistance and dyslipidemia in db/db mice
L. Long, Q. Huang, T. Song, Z. Dai
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
Grantová podpora
2022JJ70134
Hunan Provincial Natural Science Foundation of China - China
2022JJ80120
Hunan Provincial Natural Science Foundation of China - China
NLK
Directory of Open Access Journals
od 2019
ROAD: Directory of Open Access Scholarly Resources
od 2002
PubMed
38912862
DOI
10.32725/jab.2024.009
Knihovny.cz E-zdroje
- MeSH
- beta-buňky účinky léků metabolismus MeSH
- diabetes mellitus 2. typu * farmakoterapie metabolismus MeSH
- dyslipidemie * farmakoterapie metabolismus MeSH
- hyperglykemie farmakoterapie metabolismus MeSH
- inositol * farmakologie terapeutické užití MeSH
- inzulin metabolismus krev MeSH
- inzulinová rezistence * MeSH
- krevní glukóza metabolismus účinky léků MeSH
- mezenchymální kmenové buňky metabolismus účinky léků MeSH
- myši MeSH
- tukové buňky metabolismus účinky léků MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Myo-inositol (MI), present in a variety of foods, is essential in several important processes of cell physiology. In this study, we explored the protective effects of MI against hyperglycemia and dyslipidemia in db/db mice, a typical animal model of type 2 diabetes mellitus (T2DM). MI supplement effectively suppressed the high plasma glucose and insulin levels and markedly relieved the insulin resistance (IR) in the db/db mice, comparable to metformin's effects. In MIN6 pancreatic β cells, MI also restrained the upsurge of insulin secretion stimulated by high-concentration glucose but had no impact on the promoted cell proliferation. Moreover, MI abated the enhanced plasma triglyceride and total cholesterol levels in the db/db mice. Notably, the lipid droplet formation of mesenchymal stem cells (MSCs) from db/db mice was significantly diminished after the treatment of MI, indicating that MI could effectively inhibit the differentiation of db/db mouse MSCs into adipocytes. However, MI regretfully failed to control obesity in db/db mice. This work proved that MI significantly helped db/db mice's metabolic disorders, indicating that MI has potential as an effective adjunctive treatment for hyperglycemia and dyslipidemia in T2DM patients.
Central South University Xiangya Hospital Department of Neurosurgery Changsha China
Hunan Provincial People's Hospital Department of Pharmacy Changsha China
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24011947
- 003
- CZ-PrNML
- 005
- 20250507141029.0
- 007
- ta
- 008
- 240711s2024 xr ad f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.32725/jab.2024.009 $2 doi
- 035 __
- $a (PubMed)38912862
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Long, Lingzhi $u Hunan Provincial People's Hospital (The First-affiliated Hospital of Hunan Normal University), Department of Pharmacy, Changsha, China
- 245 10
- $a Myo-inositol rescued insulin resistance and dyslipidemia in db/db mice / $c L. Long, Q. Huang, T. Song, Z. Dai
- 520 9_
- $a Myo-inositol (MI), present in a variety of foods, is essential in several important processes of cell physiology. In this study, we explored the protective effects of MI against hyperglycemia and dyslipidemia in db/db mice, a typical animal model of type 2 diabetes mellitus (T2DM). MI supplement effectively suppressed the high plasma glucose and insulin levels and markedly relieved the insulin resistance (IR) in the db/db mice, comparable to metformin's effects. In MIN6 pancreatic β cells, MI also restrained the upsurge of insulin secretion stimulated by high-concentration glucose but had no impact on the promoted cell proliferation. Moreover, MI abated the enhanced plasma triglyceride and total cholesterol levels in the db/db mice. Notably, the lipid droplet formation of mesenchymal stem cells (MSCs) from db/db mice was significantly diminished after the treatment of MI, indicating that MI could effectively inhibit the differentiation of db/db mouse MSCs into adipocytes. However, MI regretfully failed to control obesity in db/db mice. This work proved that MI significantly helped db/db mice's metabolic disorders, indicating that MI has potential as an effective adjunctive treatment for hyperglycemia and dyslipidemia in T2DM patients.
- 650 _2
- $a zvířata $7 D000818
- 650 12
- $a inzulinová rezistence $7 D007333
- 650 12
- $a dyslipidemie $x farmakoterapie $x metabolismus $7 D050171
- 650 12
- $a inositol $x farmakologie $x terapeutické užití $7 D007294
- 650 _2
- $a myši $7 D051379
- 650 12
- $a diabetes mellitus 2. typu $x farmakoterapie $x metabolismus $7 D003924
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a inzulin $x metabolismus $x krev $7 D007328
- 650 _2
- $a mezenchymální kmenové buňky $x metabolismus $x účinky léků $7 D059630
- 650 _2
- $a krevní glukóza $x metabolismus $x účinky léků $7 D001786
- 650 _2
- $a beta-buňky $x účinky léků $x metabolismus $7 D050417
- 650 _2
- $a tukové buňky $x metabolismus $x účinky léků $7 D017667
- 650 _2
- $a hyperglykemie $x farmakoterapie $x metabolismus $7 D006943
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Huang, Qi $u Hunan Provincial People's Hospital (The First-affiliated Hospital of Hunan Normal University), Department of Pharmacy, Changsha, China
- 700 1_
- $a Song, Tao $u Central South University, Xiangya Hospital, Department of Neurosurgery, Changsha, China
- 700 1_
- $a Dai, Zhijie $u The Second Xiangya Hospital of Central South University, Department of Metabolism and Endocrinology, National Clinical Research Center for Metabolic Diseases, Changsha, China
- 773 0_
- $w MED00012667 $t Journal of applied biomedicine $x 1214-0287 $g Roč. 22, č. 2 (2024), s. 74-80
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38912862 $y Pubmed
- 910 __
- $a ABA008 $b B 2301 $c 1249 $y p $z 0
- 990 __
- $a 20240711 $b ABA008
- 991 __
- $a 20250507141026 $b ABA008
- 999 __
- $a ok $b bmc $g 2316457 $s 1223799
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 22 $c 2 $d 74-80 $e 20240614 $i 1214-0287 $m Journal of applied biomedicine $n J Appl Biomed $x MED00012667
- GRA __
- $a 2022JJ70134 $p Hunan Provincial Natural Science Foundation of China $2 China
- GRA __
- $a 2022JJ80120 $p Hunan Provincial Natural Science Foundation of China $2 China
- LZP __
- $b NLK124 $a Pubmed-20240711